

116TH CONGRESS
2D SESSION

H. R. 7674

To require the Director of the Centers for Disease Control and Prevention to create a standardized method for State, Tribal, and local health departments to report to the Centers with respect to COVID–19, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JULY 20, 2020

Mr. BEYER (for himself, Ms. SEWELL of Alabama, Mr. GARCÍA of Illinois, Mr. SERRANO, Ms. SCANLON, Mr. HORSFORD, Mr. CONNOLLY, Mr. PERLMUTTER, Mr. LIPINSKI, Mr. CISNEROS, Ms. DEAN, Mr. PASCRELL, Mr. SUOZZI, Mr. LANGEVIN, Ms. MCCOLLUM, Mrs. AXNE, Ms. PORTER, Mr. GARAMENDI, Mr. GRIJALVA, Mrs. WATSON COLEMAN, Ms. GABBARD, Mr. CÁRDENAS, Mr. WELCH, Mrs. LAWRENCE, Mr. SABLAN, Ms. SHERRILL, Ms. SPANBERGER, Mr. GONZALEZ of Texas, and Mr. ENGEL) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To require the Director of the Centers for Disease Control and Prevention to create a standardized method for State, Tribal, and local health departments to report to the Centers with respect to COVID–19, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “COVID–19 Data
3 Transparency Act”.

4 **SEC. 2. STANDARDIZED METHOD FOR HEALTH DEPART-**
5 **MENT REPORTING.**

6 (a) IN GENERAL.—Not later than 30 days after the
7 date of enactment of this Act, the Director of the Centers
8 for Disease Control and Prevention shall create a stand-
9 ardized method for State, Tribal, and local health depart-
10 ments to report to the Centers with respect to COVID–
11 19 the following:

12 (1) Daily hospitalizations of patients in the re-
13 spective jurisdiction with a confirmed or presumed
14 case of COVID–19.

15 (2) Daily numbers of such patients in the inten-
16 sive care unit.

17 (3) Daily numbers of such patients on ventila-
18 tors.

19 (4) How long such patients have been in the
20 hospital.

21 (5) Daily numbers of diagnostic and serological
22 tests administered for SARS–CoV–2 with respect to
23 patients in the respective jurisdiction, disaggregated
24 by—

25 (A) the type of test; and

1 (B) the testing positivity rate of each type
2 of test.

3 (6) The sensitivity and specificity of each such
4 type of test.

5 (7) Daily numbers and percentages of contacts
6 traced with respect to patients in the respective ju-
7 risdiction.

8 (8) The rate of transmission of SARS-CoV-2
9 in the respective jurisdiction.

10 (b) POSTING BY CDC.—The Director of the Centers
11 for Disease Control and Prevention shall—

12 (1) post the information described in para-
13 graphs (1) through (8) of subsection (a), to the ex-
14 tent such information is in the possession of the
15 Centers, on the public website of the Centers, except
16 that such posting shall exclude any individually iden-
17 tifiable information; and

18 (2) to the extent feasible disaggregate such in-
19 formation by State, Tribal, and local jurisdiction.

20 (c) UPDATES.—The Director of the Centers for Dis-
21 ease Control and Prevention—

22 (1) shall, as appropriate, periodically update the
23 method posted under subsection (a); and

- 1 (2) may revise and expand the reporting cat-
- 2 egories listed in such subsection.

○